Baxter buys blood disorder assets from Archemix
Blood therapy products maker Baxter International Inc said it would buy the blood disorder-related assets of privately held biopharmaceutical firm Archemix for a $30 million upfront payment.
Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, announced today that it has completed the sale of certain assets related to its hemofiltration product line to Baxter International Inc., consistent with the previously announced terms of the agreement.